GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
- 1953.248
- +22.618+1.17%
Pfizer Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Eli Lilly and Co Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Structure Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and UnitedHealth (UNH)
Amgen Analyst Ratings
Argus Research Maintains Buy on Amgen, Raises Price Target to $340
Viking Therapeutics Analyst Ratings
Pfizer Analyst Ratings
Eli Lilly and Co Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald Reiterates Overweight on Eli Lilly and Co, Maintains $885 Price Target
Novo Nordisk Analyst Ratings
BMO Capital Maintains Outperform on Novo Nordisk, Maintains $163 Price Target
B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Jefferies Financial raised the target price of Eli Lilly and Co. to $1015.